alexa Clinical Outcome for PVL+ Staphylococcus Aureus Associated Necrotising Pneumonia may be Optimised Through Combination of Prompt Antimicrobial and Anti-Toxin Treatment | Open Access Journals
ISSN: 2376-0311
JBR Journal of Clinical Diagnosis and Research
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Clinical Outcome for PVL+ Staphylococcus Aureus Associated Necrotising Pneumonia may be Optimised Through Combination of Prompt Antimicrobial and Anti-Toxin Treatment

Tom Marrs1,2* and Colin Michie3

1Children’s Allergies, Evelina Children’s Hospital, St Thomas’ Hospital, Westminster Bridge Road, London, UK

2Division of Asthma, Allergy and Lung Biology, King’s College London, UK

3Department of Paediatrics, Ealing Hospital, London, UK

Corresponding Author:
Marrs T
Children’s Allergies, Evelina Children’s Hospital
St Thomas’ Hospital, Westminster Bridge Road, London, UK
Tel: +44 (0) 20 7188 4877
Fax: +44 (0) 20 7188 978
E-mail: [email protected]

Received date: March 19, 2014; Accepted date: August 25, 2014; Published date: September 02, 2014

Citation: Marrs T, Michie C (2014) Clinical Outcome for PVL+ Staphylococcus Aureus Associated Necrotising Pneumonia may be Optimised Through Combination of Prompt Antimicrobial and Anti-Toxin Treatment. J Clin Diagn Res 2:108. doi:10.4172/2376-0311.1000108

Copyright: © 2014 Marrs T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at JBR Journal of Clinical Diagnosis and Research

Abstract

Necrotising pneumonia caused by Panton-Valentine Leukocidin Staphylococcus aureus confers a high mortality. We describe a child presenting with sepsis and necrotising pneumonia. Septicaemia caused by Panton-Valentine Leukocidin Staphylococcus may not be adequately treated with antibiotics to which it appears sensitive through standard culture techniques. Some evidence suggests that early anti-toxin therapy may better optimise clinical outcomes.

Keywords

Panton-valentine; PVL; Staphylococcus; Sepsis; Antitoxin

Introduction

Necrotising pneumonia has a mortality rate of 56-61% and is associated with necrotic ulcerations of the tracheal and bronchial mucosa, with massive haemorrhagic necrosis of interalveolar septa [1]. Commonly, young immune-competent individuals present with a history of progressive skin - soft tissue infection and associated sepsis, before succumbing to respiratory involvement through likely haematogenous spread and resultant multi-organ disease [2]. We present a typical such case to demonstrate the challenges of making an early diagnosis, and review the evidence for anti-toxin therapy.

Case

A previously well 12 year old Somali boy presented to our Accident and Emergency department with a single day history of peri-orbital oedema, vomiting and fever to 39°C which was treated at home with Ibuprofen. He had no preceding atopic history and his only preceding skin infection was that of tinea capitis at 5 years of age. He had not previously been admitted to hospital or been abroad in the last five years, although his mother worked as a nurse on an in-patient adult ward and his grandmother had been admitted with recurrent exacerbations of Chronic Obstructive Airways Disease. He was centrally tender on palpating his abdomen with afebrile tachycardia and bilateral periorbital oedema. He showed no sign of respiratory distress. A differential diagnosis of viral gastro-enteritis or early appendicitis compounded by non-steroidal anti-inflammatory allergy was ascertained. He was discharged with a single dose of 20 mg of soluble Prednisolone and advised to return in case of any deterioration.

Fourty hours later, he returned to hospital, intermittently confused and complaining that his right leg, back and abdomen were painful. His right leg rested flexed at the knee and externally rotated. His right popliteal fossa was tender, although he allowed full range of passive movement bilaterally of hips and knees. His chest examination revealed quiet air entry with bilateral fine crepitations throughout and chest radiograph showed bilateral patchy infiltration and consolidation. He received 2.5 g (80 mg/kg) of intravenous Ceftriaxone (Roche) and 1.4 g (50 mg/kg) of Flucloxacillin (GSK). Shortly after his initial assessment, he became flushed, febrile and demonstrated profound respiratory distress, his saturations dropping from 95 to 80% in air and subsequently suffered circulatory collapse. 600 ml (20 ml/kg) of 0.9% NaCl Saline, one 300 ml (10 ml/kg) pack of fresh frozen plasma and 200 mg (7 mg/kg) of Gentamycin (Roche) were administered, according to his estimated weight. He passed dark brown urine which tested positive for myoglobin. 12 hours later, he was electively intubated and transferred to intensive care, where his respiratory secretions were consistently blood stained.

His first blood culture grew Staphyloccocus aureus at 16 hours, sensitive to methicillin, resistant to penicillin and ciprofloxacin, which on toxin typing revealed PVL and enterotoxins G and I.

On intensive care, he was treated for PVL sepsis with complicating cardiogenic shock requiring inotropic support (15 mcg/kg/min of Dopamine and 0.5 mcg/kg/min of Noradrenaline which was weaned within 48 hours), necrotising pneumonia, disseminated intravascular coagulation, and required a single dose of Vitamin K (7.5 mg Konakion, Roche) with two red packed cell transfusions of 360 ml each Table 1. His white cell count dropped to 1500 leukocytes per millilitre and his antibiotic regime was changed to 600 mg (maximum dose) intravenous Linezolid (Pharmacia) twice daily, 320 mg (10 mg/kg) intravenous Clindamycin (Pharmacia) four times daily and 320 mg (10 mg/kg) naso-gastric Rifampicin (Aventis Pharma) on his fifth day of admission, while his inflammatory markers were peaking. Little progress was evident, until he received two days of anti-toxin treatment, 30 g (1 mg/kg) of intravenous immunoglobulin (Flebogamma 5%) infusions. He thereafter demonstrated clinical improvement and was extubated seven days subsequently. Ultrasound demonstrated soft tissue infection of right knee, left ankle and septic arthritis of left knee, which was drained of fluid culturing further PVL Staphylococcus aureus. Subsequent MRI showed right sacroiliac osteomyelitis, right gluteal muscle inflammation with fluid around left trochanter and right ankle. No repeated drainage procedures were necessary and he was discharged on the thirty-first day of admission, whilst receiving 2.4 g of intravenous Ceftriaxone by per-cutaneous catheter each morning, 300 mg of oral Rifampicin twice daily and 300 mg of oral Clindamycin four times daily. These antibiotics were continued for 18 weeks, whereupon he was discharged from the orthopedic team and his local physiotherapy service without known long-term sequel. Our case did not experience any hair loss or peeling of finger-tip skin throughout his illness. His mother and father were screened for S. aureus while he was admitted on intensive care, returning negative results and his household contacts underwent decolonization.

  Day 1 Day 2 Day 3 Day 7 Day 15
Haemoglobin g/dl 13.8 10.6 6.7 7.2 8.5
White cell x109 4.4 1.6 1.5 3.4 19
Neutrophils x109 3.7 0.9 1.1 2.7 16
Platelets x109 127 82 74 87 381
Prothrombinsecs 16.1 15.0 14.0 14.0 11.9
APTT secs 54.9 57.7 65.4 61.0 34
Fibrinogen g/L 5.05 4.56 4.4 4.1 3.8
INR 1.50 1.40 1.38 1.28  
CRP 246 >250 >250 >250 176

Table 1: Hematological parameters through acute deterioration and recovery.

Discussion

PVL+ staphylococcal sepsis with necrotizing pneumonia is difficult to manage. Early recognition and treatment with both antibiotic and anti-toxin therapy may optimize clinical outcomes for this aggressive disease.

Our case presented to Accident and Emergency without respiratory distress, re-presenting in shock 36 hours later and de-compensating shortly afterward with blood stained secretions aspirated on ventilation. His disease progressed despite being treated with antibiotics to which his strain was susceptible, until anti-toxin therapy was instituted on the fifth day of admission.

PVL Staphylococcal infection incidence is likely increasing and was estimated at 3.38 per 100,000 in 2009 [3]. Data from the UK Staphylococcal Reference Laboratory in 2005 demonstrated PVL S. aureus constituted 1.6% of bacteraemic isolates sent for analysis [4]. From 2005 to 2009, a ten-fold increase in number of PVL isolates was recorded. In contrast to the American experience, the majority of reported European isolates are methicillin susceptible [1,2,5]. The majority of methicillin susceptible PVL S. aureus isolates are associated with soft tissue infection and abscesses, and a proportion of these progresses to sepsis [5].

The progression of PVL+ staphyloccal sepsis may be attenuated the combination of instituting both bactericidal treatment and antitoxin therapy. In clinical practice, seemingly appropriate antibiotics identified through in vitro susceptibility profiling may not prevent considerable disease progression when used in isolation [1,2]. Therefore, early recognition of potential toxin driven disease is crucial, and risks of administering anti-toxin treatment should be balanced with their potentially life-saving capacity for patients presenting with toxin associated sepsis.

In vitro work has demonstrated that Clindamycin and Linezolid have protein-synthesis inhibiting characteristics capable of dramatically impairing the capacity of S. Aureus strains to manufacture phenolsoluble modulin peptides [6]. Cases receiving prompt anti-toxin therapy in combination with appropriate antibiotic treatment appear to achieve beneficial outcomes in practice [7]. Without this, outcomes may be impaired, particularly where penicillin agents used below the minimum inhibitory concentration which may promote more rapid dispersal and manufacture of toxins [8].

The UK Health Protection Agency outlines that PVL S. aureus should be suspected amongst individuals and families with a history of repeated or severe soft tissue infection, necrotising pneumonia and close contacts thereof [9]. A recent UK case series highlights that minor preceding soft tissue injury, contact sport in young adolescents and adults, non-white ethnicity and preceding respiratory infection are risk factors for developing PVL S. aureus infection [10]. The authors also speculate that ascertaining such features in the history may aid earlier diagnosis [3]. However, such factors are commonplace amongst those attending primary and secondary health care facilities worldwide. Our case attended for emergency care whilst confused, unable to describe any preceding illness or injury. Nonetheless, a scab was dislodged from his left lower leg during his second day in intensive care, discharging PVL+ S. aureus. A pragmatic clinical approach must be recommended to clinicians in urgent care centers, emphasizing the importance of noting histories of preceding staphylococcal infection, recognizing early sepsis and arranging prompt anti-toxin management early for such patients.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 11732
  • [From(publication date):
    December-2014 - Sep 24, 2017]
  • Breakdown by view type
  • HTML page views : 7909
  • PDF downloads :3823
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords